VectorY expands PIONEER-ALS trial to 36 participants
VectorY Therapeutics expanded its Phase 1/2 PIONEER-ALS clinical trial of VTx-002 from 12 to 36 participants. The global, multicenter, open-label, dose escalation study is evaluating two dose levels to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects in adults with amyotroph
<p>VectorY Therapeutics expanded its Phase 1/2 PIONEER-ALS clinical trial of VTx-002 from 12 to 36 participants. The global, multicenter, open-label, dose escalation study is evaluating two dose levels to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects in adults with amyotroph</p>